Ionis Pharmaceuticals Q2 2025 earnings highlight strong Tryngolza sales, increased 2025 revenue guidance, and upcoming Donidalorsen FDA approval.

Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) (the “Company”) today reported financial results and provided key updates for the second quarter ended June 30, 2025.

Ionis Pharmaceuticals and Ono Pharmaceutical announced a global license agreement for sapablursen in polycythemia vera in March 2025.

Meanwhile, Sapablursen (ONO-0530), developed by Ono Pharmaceutical, introduces an antisense oligonucleotide strategy targeting thrombopoietin receptor mRNA.

Strategic partnerships with Biogen, GSK, and Sobi, as well as licensing income from deals like the $280 million sapablursen contract, support Ionis Pharmaceuticals, Inc.’s (NASDAQ:IONS ...

Strategic partnerships with Biogen, GSK, and Sobi, as well as licensing income from deals like the $280 million sapablursen contract, support Ionis Pharmaceuticals, Inc.’s (NASDAQ:IONS ...

Additionally, Ionis has entered a strategic partnership with Ono Pharmaceuticals to develop sapablursen for polycythemia vera, which Oppenheimer views positively, maintaining an Outperform rating with ...

Oppenheimer has maintained an Outperform rating on Ionis with a price target of $78, noting a recent partnership with Ono Pharmaceuticals to develop sapablursen for polycythemia vera.